Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A <i>Post-Hoc</i> Analysis of Three Phase III Clinical Trials of Belimumab.

Front Immunol · 2022 · PMC9015703 · PMID 35444642

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceP=0.071so close (0.05 < p ≤ 0.1)

showed a trendno p-value reported

Patients who developed at least one severe flare from week 24 onwards showed a trend towards less prominent decreases in anti-dsDNA levels through week 24 compared with patients who did not develop severe flares (-10.5 versus -20.5%), which however did not reach statistical significance (P=0.071).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.